Article

Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravis

2018-12-13

Abstract excerpt

Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by autoantibodies that bind to functional membrane proteins at the neuromuscular junction. Most patients have autoantibodies to the acetylcholine receptor (AChR), but a subset of patients instead have autoantibodies to muscle specific tyrosine kinase (MuSK). MuSK is an essential component of the Agrin/Lipoprotein re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 82618f52-3abc-56fc-824c-83aa74b4c354
DOI: 10.1101/488247

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravisDOI 10.1101/488247Read

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity Read

MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificitySemantic proximity Read

A primary human muscle cell-based assay for detecting myasthenia gravis autoantibody binding and assessing AChR cluster impairmentSemantic proximity Read

The agrin/muscle‐specific kinase pathway: New targets for autoimmune and genetic disorders at the neuromuscular junctionSemantic proximity Read

Timing and localization of myasthenia gravis-related gene expressionSemantic proximity Read

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSKSemantic proximity Read

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read

Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravisSemantic proximity Read

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesSemantic proximity Read

Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep SequencingSemantic proximity Read

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsSemantic proximity Read